Blagoveschensk, Blagoveshchensk, Russian Federation
Blagoveschensk, Blagoveshchensk, Russian Federation
The analysis of the implementation of prevention programs, using materials and methods of epidemiological and statistical monitoring of the population incidence of pneumonia and generalized regional experience of complex of organizational, methodological and control activities to prevention of pneumococcal disease in the territory of the Amur region. Pneumococcal conjugate vaccine "Prevenar-13" and flu vaccine were used for immunization against acute respiratory viral infections and pneumococcal infection. We take into account information about the rate of pneumonia and respiratory viral infections for the period from 2010 to 2015. To assess the effectiveness of vaccination we used indicators and specific criteria. Comparative statistical analysis revealed a high degree of efficiency of the regional programs with the use of methods of pneumococcal immunization: the coefficient of efficiency of preventive vaccination reaches 75-100% using the incidence of pneumonia as indicator. The incidence of pneumonia in vaccinated contingent decreased by 2.3 times for 2 years in the region.
pneumonia, prevention of pneumococcal infections, pneumococcal vaccine, effectiveness of vaccination.
1. Vaccine prevention of pneumococcal infection. Federal clinical guidelines. Moscow; 2015 (in Russian).
2. Kolosov V.P., Kochegarova E.Yu., Naryshkina S.V. Community-acquired pneumonia (clinical course, predicting outcomes). Blagoveshchensk; 2012 (in Russian).
3. Kolosov V.P., Manakov L.G., Kiku P.F., Polyanskaya E.V. Respiratory diseases in the Far East of Russia: epidemiologic and social-hygienic aspects. Vladivostok: Dal´nauka; 2013 (in Russian).
4. Kolosov V.P., Kurganova O.P., Tezikov N.L., Gulevich M.P., Manakov L.G., Trotsenko O.E., Perepelitsa A.A., Pavlova I.I., Burdinskaya E.N., Lipskaya N.A. Epidemiologic features of community-acquired pneumonias in the Amur region, the problems of their solution. Bûlleten´ fiziologii i patologii dyhaniâ 2014; 53:8–17 (in Russian).
5. Kolosov V.P., Kurganova O.P., Tezikov N.L., Gulevich M.P., Manakov L.G., Trotsenko O.E., Perepelitsa A.A., Pavlova I.I., Burdinskaya E.N., Lipskaya N.A. Organization of community-acquired pneumonia prevention in overflow zones of the Amur region. Bûlleten´ fiziologii i patologii dyhaniâ 2014; 53:18–24 (in Russian).
6. Malakhov A.B., Kharit S.M., Kramar´ L.V., Ksenofontova O.L., Lopushov D.V., Migunova O V., Pavlinova E.B., Rychkova O.A. The effectiveness of regional programs of vaccination pneumococcal infection in children. Zdravookhranenie 2014; 1:113–126 (in Russian).
7. About the confirmation of sanitary-epidemiologic rules 3.1.2.3116-13 №62 «The prevention of community-acquired pneumonias»: the resolution of the chief state sanitary doctor of RF. Available at: www.16.rospotrebnadzor.ru/311/-/asset_publisher/u0No/content/ (in Russian).
8. Resolution of Expert Forum Russian and International Approaches to Vaccination against Pneumococcal Disease in High Risk Children and Adults. Pulmonology 2015; (5):633–637 (in Russian).
9. Sidorenko S.V., Savinova T.A., Ilyina E.N., Syrochkina M.A. Population Pattern of Pneumococci with Lower Susceptibility to Penicillin and Prospects of Antipneumococcal Vaccination to Control Antibiotic Resistance Distribution. Antibiotiki i khimioterapiya 2011; 56(5-6):11–18 (in Russian).
10. Chuchalin A.G., Bilichenko T.N., Osipova G.L., Kurbatova E.A., Egorova N.B., Kostinov M.P. Vaccine prophylaxis of respiratory diseases in primary health care to the population. Clinical recommendations. Pulmonology (Suppl.); 2015; 25(2) (in Russian).
11. Chuchalin A.G. Pneumonia as an actual medical problem of the 21th century. Pulmonology 2015; (2):133–142 (in Russian).
12. EMA Oct. 2011: European public assessment report (EPAR) for PCV13 (First published in May 2009, last updated in October 2011) EMA / 562289 / 2011. Available at: www.ema.europa.eu
13. Immunization Schedules for Healthcare Professionals / CDC. Available at: www.cdc.gov/vaccines/schedules/hcp/
14. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly Rep. 2012; 61(40):816–819.
15. WHO Publication. Pneumococcal vaccines WHO position paper (2012) recommendations. Vaccine 2012; 30(32):4717–4718. DOI: 10.1016/j.vaccine.2012.04.093.
